Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies is focusing on developing treatments for osteosarcoma and other solid tumors, with a potential market potential of $300M in Europe and $50M in 2027 sales. The company is expected to have key milestones, such as pre-BLA engagement with the FDA and regulatory meetings in Q2 2026, and potential accelerated approval decisions and PRV monetization in the second half of 2026. However, there are risks involved in the company's clinical and regulatory processes, as well as potential challenges in financing and maintaining market share.

Bears say

OS Therapies is a clinical-stage biopharmaceutical company that is developing a lead drug, OST-HER2, for the prevention or delay of recurrence in patients with fully resected pulmonary metastatic osteosarcoma. Despite promising potential, the company's pipeline is still in the preclinical stage and there is no current revenue. The recent initiation of a rolling review by the EMA is a positive validation, but more development and regulatory hurdles may still lie ahead before the company can generate any meaningful revenue.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.